Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962610 | 0.83 | CYP2A6 (0.38) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL31009687 | 0.83 | CYP2A6 (0.38) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL144441 | 0.77 | CYP2A6 (0.57) | RAB9ACYP2A6DYRK1AALDH1A1MAPT | |
| SCHEMBL3125932 | 0.77 | HSP90AA1 (0.55) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL21326404 | 0.76 | HSP90AA1 (0.53) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL18858489 | 0.75 | HSP90AA1 (0.49) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL3478352 | 0.75 | HSP90AA1 (0.49) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL13654389 | 0.74 | BACE1 (0.53) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL144549 | 0.74 | CYP2A6 (0.42) | CYP2A6ALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2090846 | 0.74 | HSP90AA1 (0.52) | HSP90AA1LMNAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376125-A1 | MECHANOPHORE WITH FORCE TRIGGERED STEREOCHEMISTRY CONVERSION | SYRACUSE UNIVERSITY (US) | 2024-11-14 | — | — | US | disclosed |
| CN-117510485-A | Isoxazoline compounds for controlling invertebrate pests | FMC公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| CN-117098757-A | GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-4895860-A | ANTIDIABETIC, ANTILIPEMIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0073663-B1 | THROMBOXANE SYNTHETASE INHIBITORS, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pfizer Limited (GB) | 1986-06-18 | — | — | EP | disclosed |
| US-4590200-A | NON-INHIBITION OF PROSTACYCLIN SYNTHETASE OR CYCLO-OXYGENASE | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4496572-A | Benzo-fused thromboxane synthetase inhibitors | PFIZER INC. (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0073663-A2 | Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them | Pfizer Limited (GB) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | HSP90AA1 4689/4885LMNA 1751/4885MEN1 4378/4885 |
| US-20240376125-A1 | MECHANOPHORE WITH FORCE TRIGGERED STEREOCHEMISTRY CONVERSION | PCNA, CCNE2, PIEZO1 | HSP90AA1 3324/4885LMNA 3439/4885MEN1 1298/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | HSP90AA1 2194/4885LMNA 4601/4885MEN1 4485/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | HSP90AA1 2194/4885LMNA 4601/4885MEN1 4485/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | HSP90AA1 813/4885LMNA 3168/4885MEN1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.